Sang­amo re­searcher charged with in­sid­er trad­ing in lat­est round of SEC ac­cu­sa­tions lev­eled at a biotech ex­ec

Back in ear­ly 2014, in­vestors in Sang­amo reaped some quick gains when Bio­gen an­nounced that it had just struck a deal with the gene edit­ing com­pa­ny. 

In­vestors thrilled to the news that Bio­gen was pay­ing Sang­amo $SG­MO $20 mil­lion up­front with $300 mil­lion in biobucks on the ta­ble to hunt for a cure to sick­le cell dis­ease and be­ta-tha­lassemia, dri­ving the stock up 38%.

One of those in­vestors who ben­e­fit­ed was a day trad­er named Steven Fishoff, who had tipped off a group of four oth­er traders about what was com­ing. To­geth­er, they al­leged­ly bagged $1.5 mil­lion in a quick score.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER